ICH E6(R3) became effective in the EU on July 23, 2025, with the FDA following in September and the UK making compliance legally required on April 28, 2026. For site and sponsor teams, this isn't a minor update. The guideline introduces risk proportionality as a formal principle, embeds Quality by Design into trial conduct, and shifts from documenting everything equally to tailoring records based on what actually protects participants and data reliability.

The terminology matters: E6(R3) moves from "documents" to "records," meaning your TMF now must capture not just files but the full metadata layer (version history, approvers, timestamps, audit trails). Protocols must now explicitly identify critical-to-quality factors and include pre-specified deviation criteria before the trial starts. Essential records are no longer one-size-fits-all. Sponsors make risk-proportionate decisions about what belongs in the TMF based on trial design, with ongoing access and oversight obligations even when records live in vendor systems.

If you're running or supporting trials in ICH regions, your documentation practices need to reflect these changes now. The old playbook of uniform documentation intensity across all trials no longer aligns with the standard.